Enlibrium
San Diego
About Enlibrium
Enlibrium is developing novel drugs based on metformin to treat a range of different cancers by reducing cancer energy consumption and reestablishing energy balance. Given their high growth rate and energy requirements, cancers are particularly sensitive to agents that reduce their energy production. Enlibrium was founded based on technology exclusively licensed from UCLA and developed in laboratories headed by Michael Jung, Ph.D. and Richard Pietras, M.D., Ph.D. Enlibrium's investors are Avalon Ventures, TPG Biotech, Correlation Ventures and Osage University Partners.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $15.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Dec 2015)
Industries & Categories
Energy, Health Care, Medical
Canonical: https://fsome.com/organization/enlibrium-1096845 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.